Corporate Presentation

CORPORATE PRESENTATION
WE ARE
HETERO
A global leader in ARV APIs & Formulations,
with proven capabilities in development, manufacturing
and marketing of Intermediates, Bulk Drugs and
Finished Formulations of Chemical & Biologic Drugs.
 OUR FOUNDER

Hetero was founded in the year 1993, by the visionary

scientist Dr. BPS Reddy.

Under his leadership, Hetero has risen to become the

largest closely held pharmaceutical company in India
and a world leader in the production of anti-retroviral
drugs.
Dr. BPS Reddy,
CMD, Hetero Group of Companies
 HETEROS HISTORY IN THE MAKING
Our first API manufacturing facility
at Hyderabad began its operations
Established state-of- the-art R&D centre
Hetero Research Foundation (HRF)
Emergence as one of the first Indian
companies offering affordable ARV APIs
HRF recognized for developing processes
for about 20 APIs within 3 years
First US FDA approval for API manufacturing
facility at Hyderabad, India
One of the first companies to develop lifesaving
drug Oseltamivir for Bird Flu and Swine Flu
US FDA approval for finished dosage
manufacturing facility at Hyderabad, India
Established Asias largest SEZ complex
for APIs in Vizag, India
Established a dedicated facility to manufacture oncology
injectables
Established world class Biologics
unit in Hyderabad, India
Launched the blockbuster Hepatitis C drug Sofosbuvir
under in-licensing deal
Launched our first biosimilar product Darbapoetin alfa
Launched our second biosimilar product Rituximab in India.
Became the first company in India to launch the fixed-dose
combination Ledipasvir+Sofosbuvir
Launched the generic drug Daclatasvir
Launched our third biosimilar product Bevacizumab
in India
 NUMBERS SAY IT ALL
Amongst the worlds

25+
largest manufacturers of Global presence

20+
years of expertise
APIs state-of-the-art
120+
in pharmaceuticals & ARVs manufacturing facilities countries

15,000+ 200+ Indias

largest
employees worldwide products in portfolio closely held
pharmaceutical company
 CORE VALUES THAT DEFINE HETERO

Entrepreneurship Knowledge Quality Dynamic Caring

We derive our We recognize, We demonstrate We are Dynamic and We are committed
strength from the cultivate and Quality and passionate in our to Caring for
Entrepreneurial Spirit nourish Knowledge continuous approach to humanity and
of our team as the key driver in improvement in customers and our environment, as a
members. providing healthcare every aspect of our business. responsible
at affordable cost. practices. member of the
global family.
MISSION THAT MOTIVATES US

Accelerate alleviation of global health

challenges through innovative and
advanced therapeutics.

Enhance accessibility of affordable high

quality medicines, globally.
STRENGTHS THAT DRIVE US
1000+ scientists
Pioneering drug research and innovation
Simple dosages to complex injectables
State-of-the-art manufacturing facilities
Cutting-edge technologies
Sophisticated equipment
Compliant with cGMP practices

Expertise Experience Excellence

Vertical Integration
From concept to market
Introducing many first time generics
across major therapeutic areas
 OUR BUSINESS VERTICALS
Active
Pharmaceutical
Ingredients (APIs)
Leading supplier to generics
manufacturers
11exclusive facilities for
large scale production
Formulations Biosimilars
A world leader in
State-of- the-art manufacturing
manufacturing branded and
facilities and dedicated R&D wing
non-branded generics
Largest global supplier of Launched 3 Biosimilars -
Anti-Retroviral Drugs Darbapoetin alfa, Rituximab and
9 dedicated facilities Bevacizumab in India
2 in Clinical Trials
5 more in pipeline
Custom
Pharmaceutical
Services (CPS)
Significant economies-of- the-scale
advantages and backward integration
capabilities
Contract manufacturing of APIs,
Finished Dosages, Cytotoxic APIs and
Injectables
Technology transfer projects
 LEADER IN ARV

Committed
towards HIV/AIDS
treatment
since 1997
Partner of choice
to SCMS, UNICEF, Strong portfolio
PAHO, CHAI, of over 30 ARV
IDA Foundation combinations
and few others

Treating 4.3 million One of the

HIV/AIDS global leaders
patients globally A leading in ARVs
supplier of
ARV APIs to many
finished
dosage formulation
companies
PIONEERING RESEARCH
& DRIVING DEVELOPMENT
Focussed on developing quality products, with special emphasis on
their safety and efficacy
Excellent infrastructure
Expertise spans across formulation, analytical, packaging, IP,
technology transfer, and quality assurance
Inspiring the development of innovative, safe, environment-friendly
and cost-effective processes to deliver high-quality products
Continued investments in new areas of research such as
biosimilars and exploration of new technology platforms
 OUR KEY FOCUS AREAS

Solid Oral Injectables Novel Drug

Dosage Forms Dosage Forms Delivery
Systems Biosimilars
(IR and MR like (Liquids and
DR/SR/CR) Lyophilized) (NDDS)

Liquid Oral
Dosage Forms Pulmonary Drug New Chemical
Delivery Systems Entities
(Solutions and
(DPI and MDI) (NCEs)
Suspensions)
 MANUFACTURING CAPABILITIES

Sophisticated technologies, stringent operating procedures and compliance to Current Good

Manufacturing Procedures (cGMP)
Largest manufacturing infrastructures, scaled to deliver
Vertically integrated with end-to-end manufacturing capabilities
Regulatory approvals from various Ministries of Health and Global Regulatory Authorities
 ANNUAL PRODUCTION CAPACITIES

APIs
Reactor Volume Installed Capacity
(in Lacs) (in Lts.) (in MT) (per Annum)

73.2 36,878

Asias largest SEZ Complex for APIs, Visakhapatnam, India

ANNUAL PRODUCTION CAPACITIES
Formulations
Injectables
Tablets Capsules Liquids Pellets

45 6.7 20 360 181

million units
billion units billion units million units tonnes (includes lyophilised,
liquid & powder)

Finished formulations facility, Hyderabad, India

REGULATORY APPROVALS

US FDA | EU GMP | TGA Australia

PMDA Japan | MHRA-UK | MCC-South Africa

ANVISA Brazil | IDA | PIC/S | INVIMA - Colombia

COFEPRIS Mexico | GCC DR

OUR KEY THERAPIES
 A GLOBAL FOOTPRINT

Global Presence:
Asia, Europe, North America, Latin
America, Middle-East, Africa and
Australia

Branch Offices / Subsidiaries:

India, USA, Brazil, Mexico,
Colombia, Russia, Spain, Poland,
Dubai, Singapore, Thailand,
Philippines, China, Egypt, South
Africa, Ukraine, Argentina, Algeria,
Chile and Nigeria

Hetero is one of the largest suppliers of APIs and finished

formulations to more than 120 countries worldwide.
PRESENCE IN INDIA
Presence in the Indian pharmaceutical market since 1994
Strategic businesses include manufacturing and marketing of pharmaceutical
products
6 Specialised marketing divisions catering to wide range of therapeutic areas
Market leader in ARV and Oncology therapies
Field force in India with around 2000 employees
Catering to medical practitioners in over 400 territories in India
Focuses on enhancing patient awareness and continuing medical education
(CMEs) for doctors
PARTNERSHIPS TOWARDS PROGRESS

Our global partnerships with SCMS,

UNICEF, PAHO, CHAI and
IDA Foundation are aligned to the
purpose of innovating and providing
cost-effective medications worldwide.

Our Global Collaborations with leading

companies supports our API initiatives.

We have been successful in bringing

many first-time generics across major
therapeutic areas to our partners.
 CSR
Harvesting goodwill
Hetero is committed to the health and
prosperity of the community at large.
 Heteros prime focus areas are Green Energy

Drinking water
Education Public Health
and Sanitation

Sports Adoption of
and Games Villages

Women Swacch Bharat

Art and Culture
Empowerment Campaign
 THANK YOU

Hetero Corporate: 7-2-A2, Industrial Estates, Sanath Nagar, Hyderabad - 500 018,
Telangana, India.
Phone: +91 40 23704923/24/25. Fax: +91 40 23813359, 23704926
e-mail: contact@heterodrugs.com | www.heteroworld.com